ImmunotherapyImmunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06498635

Conditions

Lung Non-Small Cell Carcinoma

Stage II Lung Cancer AJCC v8

Stage IIIA Lung Cancer AJCC v8

Stage IIIB Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Durvalumab

Patient Observation

Questionnaire Administration

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-08-21.